B-cell receptor specific for influenza A(H1N1)pdm09 antigen (BCR (specific for A(H1N1)pdm09))

The B-cell receptor (BCR) specific for influenza A(H1N1)pdm09 antigens is a membrane-bound immunoglobulin complex essential for the adaptive immune response against the 2009 pandemic H1N1 virus. These receptors are expressed on the surface of B lymphocytes and are responsible for the direct recognition of viral proteins, most notably the hemagglutinin (HA) and neuraminidase (NA) glycoproteins. Upon antigen binding, the BCR triggers a signaling cascade that leads to B-cell activation, clonal expansion, and differentiation into plasma cells that secrete neutralizing antibodies. This process is the fundamental mechanism by which influenza vaccines, such as the H1N1 monovalent vaccines, confer protection by acting as agonists for these receptors. In the context of disease, the specificity and affinity of these BCRs determine the effectiveness of viral clearance and the breadth of cross-reactivity against drifted strains. Research has also indicated that the BCR can serve as an entry point for the virus in certain contexts, potentially leading to the infection of B cells and delayed immune responses. Furthermore, the study of these receptors is critical for the development of broadly neutralizing monoclonal antibodies and universal vaccine strategies.

Other names

A(H1N1)pdm09-specific B-cell receptor2009 pandemic H1N1-specific BCRInfluenza A virus subtype H1N1 (2009) B-cell receptorHemagglutinin-specific B-cell receptor (A(H1N1)pdm09)Apdm09-specific B-cell receptor

Antigen binding to the BCR triggers signal transduction leading to B-cell activation, proliferation, and differentiation into antibody-secreting plasma cells.